MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
- Mechanism
- Curator reviewed
The peptides in MDX-1378 are part of a protein normally found on melanocytes, or pigmented skin cells,and are also present on melanoma cells. These melanoma peptides are recognized by cytotoxic T cells in melanoma patients that are positive for HLA-A2, a human immune system compatibility antigen that is expressed in approximately half of the melanoma population. Medarex has in-licensed the MDX-1379 vaccine peptides from the National Cancer Institute (NCI).
- Primary indication
- Investigated for use/treatment in melanoma.Curator reviewed
- Code names
- MDX-1379
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with MDX-1379, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account